Celecoxib: a specific COX-2 inhibitor with anticancer properties.
about
COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesiaPathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2Cancer and the tumor microenvironment: a review of an essential relationship.Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells.Is there a common upstream link for autophagic and apoptotic cell death in human high-grade gliomas?CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance.Synthesis, docking and biological activities of novel hybrids celecoxib and anthraquinone analogs as potent cytotoxic agents.Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case-control studiesGene expression profiles identify a role for cyclooxygenase 2-dependent prostanoid generation in BMP6-induced angiogenic responses.Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.Association of cyclooxygenase-2 expression with Hp-cagA infection in gastric cancer.Cyclooxygenase-2 expression and angiogenesis in colorectal cancer.Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth.Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in Vivo.Clinical evidence for the use of aspirin in the treatment of cancer.Resveratrol directly targets COX-2 to inhibit carcinogenesis.Gastrokine 1 regulates NF-κB signaling pathway and cytokine expression in gastric cancers.Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2.In Vitro Cytotoxic Effects of Celecoxib, Mefenamic Acid, Aspirin and Indometacin on Several Cells Lines.Endoplasmic reticulum stress: its role in disease and novel prospects for therapy.An association between the PTGS2 rs5275 polymorphism and colorectal cancer risk in families with inherited non-syndromic predisposition.Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism.Polypodium leucotomos extract decreases UV-induced Cox-2 expression and inflammation, enhances DNA repair, and decreases mutagenesis in hairless miceNew insights into bone morphogenetic protein signaling: focus on angiogenesis.Cyclooxygenase-2 inhibitor is a robust enhancer of anticancer agents against hepatocellular carcinoma multicellular spheroids.Soy isoflavones and prostate cancer: a review of molecular mechanisms.Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.Functional analysis of polymorphisms in the COX-2 gene and risk of lung cancer.Molecular communication between tumor-associated fibroblasts and head and neck squamous cell carcinoma.Celecoxib inhibits β-catenin-dependent survival of the human osteosarcoma MG-63 cell line.Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma.Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells.Expression of Cyclooxygenase-1 and 2 in Epithelial Ovarian Cancer: A Clinicopathologic Study.Effect of metformin and celecoxib on cytotoxicity and release of GDF-15 from human mesenchymal stem cells in high glucose condition.Design, Synthesis, and Biological Evaluation of New Peptide Analogues as Selective COX-2 Inhibitors.Synthesis, antitumour activities and molecular docking of thiocarboxylic acid ester-based NSAID scaffolds: COX-2 inhibition and mechanistic studies.Synthesis, Molecular Docking and Anticancer Activity of Diflunisal Derivatives as Cyclooxygenase Enzyme Inhibitors
P2860
Q24653404-0B053AB7-AB38-43E3-9C59-D552CB17EB5CQ28209990-94FA00D5-771C-4543-8959-17C92F8383AEQ33806357-04A52ABA-8F25-4F70-8D0A-7D4C83BB695CQ34099447-7E7D9BFE-B85F-4008-8166-7563F03A4DBEQ34197351-0E5C2EAA-5D0E-4932-93A3-430273412130Q34437996-8FBF71C7-A809-4833-8367-A767B8B208C4Q34605197-3F126314-5631-4B58-B4C8-F54222BEBDA5Q34834711-51E2BA9E-9A55-4321-8267-109B10E9436AQ35212665-90234FE6-2886-49E1-8107-903354412E52Q35750952-72AB8331-655F-4F09-B905-492158B2D269Q36095128-2BF8F025-86A5-405A-A44D-EC080986578BQ36178294-DA5B73C9-DE8A-4070-8AA8-DDC2944DF825Q36179801-8ED12A40-CF07-4C54-8C93-4D43E0E0E328Q36253212-6B2E0CDF-AE2A-4B1A-A1DA-2CD05533D4A0Q36571885-2FFDC802-7BE6-405C-8A30-7C0B79CD90A1Q36755018-51E76D55-FED4-4409-AA90-8843C4D60AA1Q36926520-59D85CAA-819D-42FC-95AC-7AD29EC9430AQ37019900-B45838AB-E0E8-4324-A556-153B9E04A734Q37052186-26520E34-3C3D-4995-B0D3-85AD84136FB7Q37221954-884C3B40-1557-40E9-84D7-EA8119E4560FQ37288073-198E6429-A3CF-4CA7-B8CC-1B766E4EB46BQ37316967-32D61308-7437-437D-A4DD-D0B6508DD796Q37370608-32D7993A-FB30-4D25-82ED-F9B9135AD92DQ37413658-525BF196-A672-452F-A573-C329B0CDF8B5Q37433692-C5DE951E-6691-46CD-8EF5-1828C736865DQ37610047-93B44F65-5646-4374-95F5-FB78A442BA78Q37654590-82DA83C0-83CB-4DA1-BD20-ADAF304FF511Q37709099-EAC384EB-431C-4745-8DDA-91AABEBD1E47Q37732019-BE098AA7-09C4-4DE6-B183-E114F1B73D31Q38077373-5CEB97EB-FBAC-41CB-B159-C7B854885ED6Q39647695-A30B1219-EE71-4428-A031-87AC1587294AQ41109724-0CEE6E2D-4322-4ECD-87E6-913D559D8F36Q46736495-5043A7DE-FB6B-48C5-95D3-6DD39F0F8872Q47101347-3DB08C07-E664-42A7-B259-3C7270CB0E98Q47702192-AB91EAB8-9A5D-4E47-9F4F-C498471867A1Q48129133-168543D8-C44A-42D9-9A49-042E706A7214Q54977944-A28A2CC8-FD98-47B7-BEB4-5C0144837181Q58697094-CB74F86B-CA90-4F97-8D2D-BA72FB7D8AF8
P2860
Celecoxib: a specific COX-2 inhibitor with anticancer properties.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Celecoxib: a specific COX-2 inhibitor with anticancer properties.
@ast
Celecoxib: a specific COX-2 inhibitor with anticancer properties.
@en
Celecoxib: a specific COX-2 inhibitor with anticancer properties.
@nl
type
label
Celecoxib: a specific COX-2 inhibitor with anticancer properties.
@ast
Celecoxib: a specific COX-2 inhibitor with anticancer properties.
@en
Celecoxib: a specific COX-2 inhibitor with anticancer properties.
@nl
prefLabel
Celecoxib: a specific COX-2 inhibitor with anticancer properties.
@ast
Celecoxib: a specific COX-2 inhibitor with anticancer properties.
@en
Celecoxib: a specific COX-2 inhibitor with anticancer properties.
@nl
P2860
P1433
P1476
Celecoxib: a specific COX-2 inhibitor with anticancer properties.
@en
P2093
Alane T Koki
Jaime L Masferrer
P2860
P356
10.1177/107327480200902S04
P433
P577
2002-03-01T00:00:00Z